The community engagement and service mission of universities P Inman, HG Schütze NIACE, 2010 | 89 | 2010 |
Why orphan drug coverage reimbursement decision-making needs patient and public involvement CMW Douglas, E Wilcox, M Burgess, LD Lynd Health Policy 119 (5), 588-596, 2015 | 55 | 2015 |
Governing synthetic biology for global health through responsible research and innovation CMW Douglas, D Stemerding Systems and Synthetic Biology 7, 139-150, 2013 | 53 | 2013 |
Challenges for the European governance of synthetic biology for human health CMW Douglas, D Stemerding Life Sciences, Society and Policy 10, 1-18, 2014 | 50 | 2014 |
Making sense of medicines:‘lay pharmacology’and narratives of safety and efficacy A Webster, C Douglas, G Lewis Science as Culture 18 (2), 233-247, 2009 | 50 | 2009 |
Evaluating Canadians’ values for drug coverage decision making S Rizzardo, N Bansback, N Dragojlovic, C Douglas, KH Li, C Mitton, ... Value in Health 22 (3), 362-369, 2019 | 23 | 2019 |
Governing the research-care divide in clinical biobanking: Dutch perspectives M Boeckhout, CMW Douglas Life Sciences, Society and Policy 11, 1-16, 2015 | 23 | 2015 |
Governing biological material at the intersection of care and research: the use of dried blood spots for biobanking CMW Douglas, CG van El, A Faulkner, MC Cornel Croatian Medical Journal 53 (4), 390, 2012 | 20 | 2012 |
Socio-Cultural characteristics of usability of bioinformatics databases and tools C Douglas, R Goulding, L Farris, J Atkinson-Grosjean Interdisciplinary Science Reviews 36 (1), 55-71, 2011 | 16 | 2011 |
Managing huge expectations: rhetorical strategies in human genome epidemiology CMW Douglas Science & Technology Studies 18 (2), 26-45, 2005 | 13 | 2005 |
Bio-objectification of clinical research patients: impacts on the stabilization of new medical technologies CMW Douglas Bio-Objects, 59-67, 2016 | 12 | 2016 |
Researching expectations in medicine, technology and science: theory and method N Brown, C Douglas, L Eriksson, E Rodrigues, S Yearley, A Webster Positioning paper for the York Workshop of the ‘Expectations Network 23, 2005 | 12 | 2005 |
The politics of representation in the governance of emergent'secondary use'biobanks: the case of dried blood spot cards in The Netherlands C Douglas, C van El, M Radstake, S van Teeffelen, MC Cornel Studies in Ethics, Law, and Technology 6 (1), 2012 | 11 | 2012 |
Rethinking biobanking and translational medicine in the Netherlands: how the research process stands to matter for patient care CMW Douglas, P Scheltens European Journal of Human Genetics 23 (6), 736-738, 2015 | 10 | 2015 |
Public attitudes to third party access and benefit sharing: their application to UK Biobank A Webster, N Brown, C Douglas, G Lewis, J Kaye, R Tutton, N Williams London: UK Biobank Ethics and Governance Council, 2008 | 10 | 2008 |
Mothers' views on longer storage of neonatal dried blood spots for specific secondary uses SR van Teeffelen, CMW Douglas, CG van El, SS Weinreich, L Henneman, ... Public Health Genomics 19 (1), 25-33, 2016 | 9 | 2016 |
BSE in the United Kingdom A Webster, CMW Douglas, H Sato Management of Health Risks from Environment and Food: Policy and Politics of …, 2010 | 9 | 2010 |
Parental perspectives on retention and secondary use of neonatal dried bloodspots: a Dutch mixed methods study ME Jansen, LJM Van Den Bosch, MJ Hendriks, MMJ Scheffer, ... BMC pediatrics 19, 1-11, 2019 | 8 | 2019 |
Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases CMW Douglas, F Aith, W Boon, M de Neiva Borba, L Doganova, ... Orphanet Journal of Rare Diseases 17 (1), 344, 2022 | 6 | 2022 |
Editors introduction: biobanks as sites of bio-objectification N Stephens, N Brown, C Douglas Life Sciences, Society and Policy 14, 1-5, 2018 | 6 | 2018 |